Healthcare Industry News: Receptor BioLogix
News Release - December 15, 2006
Receptor BioLogix Names Four New Senior ExecutivesTeam Additions Aimed at Newly Discovered Classof Protein Therapeutics to Treat Cancer
SOUTH SAN FRANCISCO, Calif., Dec. 15 (HSMN NewsFeed) -- Receptor BioLogix, Inc., a biopharmaceutical company focused on developing a newly discovered class of protein therapeutics to treat cancer and other diseases, today announced the following individuals have joined the company's management team: Janet I. Swearson was named chief financial officer; Guy M. Gammon, M.B., B.S. (M.D.), M.R.C.P., was appointed chief medical officer; Douglas J. Kawahara, Ph.D., was named vice president of business development, and David Lilienfeld, M.D., M.P.H., was appointed senior director, regulatory and clinical affairs.
"Receptor BioLogix welcomes our newest members to the company's leadership, as we continue to grow and expand our therapeutic programs," said Thomas A. Glaze, chief executive officer. "With a Phase 3 study anticipated in 2007 for our lead clinical product Gastrimmune, and Phase 1 studies for our first Hermodulin clinical products slated for mid-2008, we are at a key point in our development that requires expansion of our existing high-caliber team."
Dr. Gammon has more than 20 years of experience in biomedical research and 10 years experience in the biotechnology industry, and brings to Receptor BioLogix broad knowledge of drug development from basic research to the clinic. He was previously vice president of clinical development at CancerVax Corp., where he had overall responsibility for conducting two Phase 3 clinical trials that enrolled over 1600 melanoma patients in 13 countries. Before that, he served as senior director, clinical trials at John Wayne Cancer Institute, where he established a Phase 3 clinical trial program and supervised numerous Phase 2 oncology trials. Previously, he was program head of immunology drug discovery at Xenova PLC, and earlier was an assistant research immunologist at UCLA. He received his M.B., B.S. (M.D. equivalent) in 1979 at the University College Hospital Medical School in London, and in 1982 he became a Member of the Royal College of Physicians.
Ms. Swearson brings to Receptor BioLogix an extensive background in successful financial management, fund raising, team building and mergers and spin-outs of early-stage life science companies. Prior to joining the company, she served as CFO, vice president, finance and operations at Threshold Pharmaceuticals, Inc., where she was instrumental in raising $151 million in public and private funds (including an IPO and a follow-on financing). Previously, she was CFO, vice president, finance and administration at Camitro Corp. until its sale to a public company. She has also served in a variety of finance and operations positions at IntraBiotics Pharmaceuticals, Inc., at Affymax participating in its IPO, sale to Glaxo Wellcome and the spin-outs of Affymetrix and Maxygen, and at Monoclonal Antibodies, Inc., until its merger with Quidel Corp. Prior to biotechnology, Ms. Swearson worked at Hewlett Packard. She received her B.A. at the University of Minnesota and her M.B.A. at the Santa Clara University.
Dr. Kawahara has more than 15 years of biotechnology industry experience, including the negotiation of in-licensing agreements, research collaborations, and pharmaceutical partnerships. Prior to joining Receptor BioLogix, he was senior director of business development at Anesiva, Inc., a biopharmaceutical company developing drugs for treating pain and inflammation. Before that, he was director of corporate development at GeneTrol Biotherapeutics, a developer of therapeutic proteins for the treatment of cancer, viral infections and autoimmune diseases. Previously, he was a member of the founding management team and corporate director of planning and business development for Xenogen Corp., and held positions of increasing responsibility at Becton Dickinson and Co. Dr. Kawahara was also director of research at Children's Hospital Orange County, and a post-doctoral fellow at UCLA. He holds a bachelor's degree in biology from UCSD, an M.B.A. in finance from CSU, Long Beach, and a Ph.D. in immunology from the University of Rochester.
Dr. Lilienfeld brings to Receptor BioLogix more than two decades of experience in pharmaceutical development and product support. A founder of the International Society for Pharmacoepidemiology in the mid-1980s, he consulted to the industry while teaching at the Mount Sinai School of Medicine. In 1992, he joined the staff of The EMMES Corp., a contract research organization, where he played a leadership role in projects covering a variety of therapeutic areas. As a medical director at the FMAS Corp., he directed the outcomes assessment program focusing on the cost and quality of care provided by the Tricare System. At the Bristol-Myers Squibb Company, he pioneered the use of pharmacoepidemiology for drug safety and market research. In 2003, he joined InterMune to direct its drug safety effort, and in 2005 moved to PDL BioPharma to build its drug safety department.
About Receptor BioLogix, Inc.
Receptor BioLogix is a privately held biopharmaceutical company focused on the discovery and development of proprietary biotherapeutics designed to modulate the receptor tyrosine kinase (RTK) family of cell-surface receptors. These receptors are involved in nearly all cancers, autoimmune and neurodegenerative diseases. The company's lead clinical product, Gastrimmune(TM), is a late-stage immunotherapeutic for treating different types of cancers including gastric and pancreatic. Receptor BioLogix's preclinical programs include Hermodulins(TM) -- broad-spectrum, anti-tumor receptor modulators, and Intron Fusion Proteins(TM) (IFP(TM)) -- a technology platform used for discovering antagonists of angiogenesis. Receptor BioLogix is based in South San Francisco, Calif.
Source: Receptor BioLogix
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.